ATXS vs. CRDF

In the year-to-date period, ATXS achieves a -51.12% return, which is significantly lower than CRDF's -36.64% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Astria Therapeutics, Inc. (ATXS) and Cardiff Oncology, Inc. (CRDF). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ATXS Sharpe Ratio is -0.86, which is lower than the CRDF Sharpe Ratio of -0.18. The chart below compares the historical Sharpe Ratios of ATXS and CRDF, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ATXS nor CRDF has paid dividends to shareholders.

The maximum ATXS drawdown since its inception was -99.72%, roughly equal to the maximum CRDF drawdown of -99.96%. Use the drawdown chart below to compare losses from any high point for ATXS and CRDF. For additional features, visit the drawdowns tool.

Astria Therapeutics, Inc. (ATXS) has a higher volatility of 26.20% compared to Cardiff Oncology, Inc. (CRDF) at 21.48%. This indicates that ATXS's price experiences larger fluctuations and is considered to be riskier than CRDF based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Astria Therapeutics, Inc. and Cardiff Oncology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.